Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucag...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-03-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
| Online Access: | http://www.dovepress.com/use-of-dpp-4-inhibitors-in-type-2-diabetes-focus-on-sitagliptin-a4147 |